Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
Thermo Fisher Scientific offers sensitive and accurate assays to probe and understand the effects of cytotoxins in biological systems. A variety of soluble biomarkers are available in different formats to best suit your research needs.
Toxicology encompasses scientific disciplines such as biology, chemistry, pharmacology, and medicine. Covering the entire biological system from cells to ecosystems, toxicology is the study of adverse effects of compounds on living organisms. The effects of toxins are influenced through their ADME (absorption, distribution, metabolism, and excretion) properties, along with their interactions with other molecules or cellular components [1].
Toxic substances interact in vivo in four steps. First, toxins must reach the blood stream. They can be absorbed through the gastrointestinal tract, skin exposure, or via lung inhalation. Once absorbed, toxic substances then enter the circulatory system through lymph and/or blood and get distributed to various organs and tissues. Next, circulating toxins undergo metabolism or biotransformation, where the compounds get chemically transformed into metabolites that may elicit a weaker or stronger toxicological effect in vivo. Finally, toxins and/or their metabolites are excreted from the body.
If a toxin can be rapidly eliminated from the body, it will have less chance of accumulating at the target site and inflicting damage. The most common methods of excretion are through the renal system or the digestive tract [2].
Toxicology testing can be broadly grouped into different categories. In research settings, synthetic and natural products/compounds are tested to assess their potential toxicological effects. In development and manufacturing of regulated materials for sale, like medicines, pesticides, cosmetics, additives, etc., all compounds must undergo toxicity testing on their final products prior to public use.
Testing methods will uncover species, organ, and dose-specific effects of compounds in question. The most common methods for testing are studying accidental exposure, in vitro studies using cell lines, and in vivo studies involving animal models [3]. At the end of testing, the LD50 of the compound is determined, which gives a value known to be a lethal dosage in 50% of the tested population.
As part of testing, it is important to understand the mechanism of action of compounds and their potential cytotoxic effects that are elicited in the body. Immunotoxicity can be measured in vitro using applications such as ELISA or ProcartaPlex multiplex immunoassays. These assays can be used to test a variety of biomarkers in the body to determine how toxins affect biomarkers. To that extent, Table 1 highlights a few examples of published data on toxicology research and testing using these methods.
A benefit of bead-based assays is the ability to multiplex—allowing simultaneous testing of different biomarkers at one time. A cost-effective and time-saving application, it requires only a small volume of sample (which is advantageous in the case of restricted/limited samples). Using this method, researchers can gain a comprehensive understanding of different toxicological effects due to the vast number of biomarkers across different species.
Reference | Summary | Target biomarkers/Panels used | Testing method |
---|---|---|---|
Effects of active and passive smoking on salivary cytokines levels in rats: A pilot study | Study of the effects of smoking on salivary cytokine levels in rats. | IL-6, IL-12p70, IFN-γ | Procartaplex |
The mycotoxin alternariol suppresses lipopolysaccharide-induced inflammation in THP-1 derived macrophages targeting the NF-κB signalling pathway | Study of the immunosuppressive effects of CD molecules & proinflammatory cytokines of the mycotoxin alternariol (metabolite of black mold) in human cells. | NF-kB, IL-8, IL-6, TNF-α , IL-10 | Procartaplex |
A new immortalized human alveolar epithelial cell model to study lung injury and toxicity on a breathing lung-on-chip system | In vitro evaluation of inhalation toxicity in a distal alveolar region model using human cell line. | IL-8 | ELISA |
Pulmonary inflammatory response from co-exposure to LPS and glyphosate | Assessment of the effects of agricultural respiratory toxins, glyphosate and endotoxin in mice and their resulting lung inflammatory responses. | TNF-α, keratinocyte chemoattractant (KC), MCP-1, MIP-2, IL-1β, IL-10, IL-13, IL-33, IL-4, IL-5, and IL-6 | ProcartaPlex |
Formaldehyde exposure induces differentiation of regulatory T cells via the NFAT‑mediated T cell receptor signalling pathway in Yucatan minipigs | Investigation of formaldehyde exposure and resulting toxicological effects on minipigs. | IL-4, IFN-γ, TNF-α | ProcartaPlex |
Topical application of the quaternary ammonium compound didecyldimethylammonium chloride activates type 2 innate lymphoid cells and initiates a mixed-type allergic response | Study of the hypersensitivity immune responses in murine models upon dermal exposure of an industrial/commercial compound. | Th1/Th2/Th9/Th17/Th22/Treg Cytokine 17-Plex Mouse ProcartaPlex Panel | ProcartaPlex |
Effects of different surface modifying agents on the cytotoxic and antimicrobial properties of ZnO nanoparticles | Evaluation of cytotoxic properties of surface-modified ZnO nanoparticles by investigating inflammatory cytokine production in human cells. | Inflammation 20-Plex Human ProcartaPlex Panel | ProcartaPlex |
Evaluation of IL-1 blockade as an adjunct to linezolid therapy for tuberculosis in mice and macaques | Assessment of reduced hematopoietic toxicity in a non-human primate model by addition of alpha-IL-IR1 to linezolid regimen. | Cytokine & Chemokine 30-Plex NHP ProcartaPlex Panel | ProcartaPlex |
Combined toxicity of air pollutants related to e-waste on inflammatory cytokines linked with neurotransmitters and pediatric behavioral problems | Study of the toxicological effects of e-waste inhalation in humans. | IL-1β, IL-6, TNF-α | ProcartaPlex |
ELISA kits can be used to detect and measure a variety of biomarkers that may be activated in toxicological settings. These kits can be used with a variety of biological sources and enable researchers to study the possible effects of toxins on different pathways in vivo, in distinct species.
ProQuantum immunoassays are highly sensitive, high-performance kits used to detect target proteins with limited volume and do not require any specialized instruments. These assays utilize proximity-based amplification technology and combine analyte-specific high-affinity antibody-antigen binding with signal detection and amplification. These capabilities are similar to qPCR and help achieve a simple yet powerful next-generation protein quantitation platform.
ProcartaPlex panels allow concurrent detection and measurement of soluble biomarkers implicated in toxin administration. Select one of our pre-configured panels described below or use the panel configurator to customize a panel best suited to your research needs associated with toxicology research and testing.
ProcartaPlex assays for kidney toxicity enable the simultaneous quantification of up to 11 toxicity targets (including FDA-recommended biomarkers) in a single well [4]. These assays are available in multiple formats including pre-configured off-the-shelf panels, simplex kits, and custom blended mix and match panels that are tested against different sample types such as urine, serum/plasma, and cell culture supernatant.
Figure 3. Urinary protein markers in acute kidney injury (AKI) and renal kidney failure (RKF) patient samples. The Kidney Toxicity 11-plex Human ProcartaPlex Panel 1 and Kidney Toxicity 9-plex Human ProcartaPlex Panel 2 were used to test key urinary protein markers in individuals. Data shows significantly increased markers in urine samples of 10 AKI and 13 RKF individuals compared to controls (healthy donor).
Cat. No. | Name | Size |
---|---|---|
EPX110-15855-901 | Kidney Toxicity 11-plex Human ProcartaPlex Panel 1 KIM-1/HAVCR/TIM-1 (Kidney injury molecule 1), Renin, Calbindin, Osteoactivin/GPNMB (Transmembrane Glycoprotein NMB), GSTA1 (Glutathione S-transferase A1), IL-18, IP-10 (CXCL10), MCP-1 (CCL2), VEGF-A, Clusterin (APO-J), RBP4 (Retinol-binding protein 4) | 96 tests |
EPX090-15856-901 | Kidney Toxicity 9-plex Human ProcartaPlex Panel 2 Uromodulin, Alpha-1-microglobulin, TFF3 (Trefoil factor 3), Osteopontin (OPN), Cystatin C, NGAL, Beta-2-microglobulin (B2M), TIMP-1, EGF | 96 tests |
EPX050-30124-901 | Kidney Toxicity 5-Plex Rat ProcartaPlex Panel 1 Calbindin, KIM-1, Osteopontin (OPN), TFF3, VEGF-A | 96 tests |
EPX050-30125-901 | Kidney Toxicity 5-Plex Rat ProcartaPlex Panel 2 Albumin, Cystatin, Clusterin (Apo-J), NGAL, TIMP-1 | 96 tests |
QuantiGene RNA gene expression assays provide a fast and high-throughput solution for multiplexed gene expression quantitation, with simultaneous measurement of up to 80 genes of interest in a single well of a 96- or 384-well plate. The QuantiGene Plex assay is based on hybridization, and incorporates branched DNA (bDNA) technology, which uses signal amplification rather than target amplification for direct measurement of RNA transcripts. The assay is run on the Luminex® platform, has a simple workflow, and does not require RNA purification. These features allow the user to merge the QuantiGene workflow for gene expression profiling with the ProcartaPlex workflow for protein quantitation (Figure 5) using the same sample.
Learn more about QuantiGene RNA assays for gene expression profiling
Figure 5. Combined workflow for QuantiGene gene expression and ProcartaPlex protein quantitation assays.
Toxicology encompasses scientific disciplines such as biology, chemistry, pharmacology, and medicine. Covering the entire biological system from cells to ecosystems, toxicology is the study of adverse effects of compounds on living organisms. The effects of toxins are influenced through their ADME (absorption, distribution, metabolism, and excretion) properties, along with their interactions with other molecules or cellular components [1].
Toxic substances interact in vivo in four steps. First, toxins must reach the blood stream. They can be absorbed through the gastrointestinal tract, skin exposure, or via lung inhalation. Once absorbed, toxic substances then enter the circulatory system through lymph and/or blood and get distributed to various organs and tissues. Next, circulating toxins undergo metabolism or biotransformation, where the compounds get chemically transformed into metabolites that may elicit a weaker or stronger toxicological effect in vivo. Finally, toxins and/or their metabolites are excreted from the body.
If a toxin can be rapidly eliminated from the body, it will have less chance of accumulating at the target site and inflicting damage. The most common methods of excretion are through the renal system or the digestive tract [2].
Toxicology testing can be broadly grouped into different categories. In research settings, synthetic and natural products/compounds are tested to assess their potential toxicological effects. In development and manufacturing of regulated materials for sale, like medicines, pesticides, cosmetics, additives, etc., all compounds must undergo toxicity testing on their final products prior to public use.
Testing methods will uncover species, organ, and dose-specific effects of compounds in question. The most common methods for testing are studying accidental exposure, in vitro studies using cell lines, and in vivo studies involving animal models [3]. At the end of testing, the LD50 of the compound is determined, which gives a value known to be a lethal dosage in 50% of the tested population.
As part of testing, it is important to understand the mechanism of action of compounds and their potential cytotoxic effects that are elicited in the body. Immunotoxicity can be measured in vitro using applications such as ELISA or ProcartaPlex multiplex immunoassays. These assays can be used to test a variety of biomarkers in the body to determine how toxins affect biomarkers. To that extent, Table 1 highlights a few examples of published data on toxicology research and testing using these methods.
A benefit of bead-based assays is the ability to multiplex—allowing simultaneous testing of different biomarkers at one time. A cost-effective and time-saving application, it requires only a small volume of sample (which is advantageous in the case of restricted/limited samples). Using this method, researchers can gain a comprehensive understanding of different toxicological effects due to the vast number of biomarkers across different species.
Reference | Summary | Target biomarkers/Panels used | Testing method |
---|---|---|---|
Effects of active and passive smoking on salivary cytokines levels in rats: A pilot study | Study of the effects of smoking on salivary cytokine levels in rats. | IL-6, IL-12p70, IFN-γ | Procartaplex |
The mycotoxin alternariol suppresses lipopolysaccharide-induced inflammation in THP-1 derived macrophages targeting the NF-κB signalling pathway | Study of the immunosuppressive effects of CD molecules & proinflammatory cytokines of the mycotoxin alternariol (metabolite of black mold) in human cells. | NF-kB, IL-8, IL-6, TNF-α , IL-10 | Procartaplex |
A new immortalized human alveolar epithelial cell model to study lung injury and toxicity on a breathing lung-on-chip system | In vitro evaluation of inhalation toxicity in a distal alveolar region model using human cell line. | IL-8 | ELISA |
Pulmonary inflammatory response from co-exposure to LPS and glyphosate | Assessment of the effects of agricultural respiratory toxins, glyphosate and endotoxin in mice and their resulting lung inflammatory responses. | TNF-α, keratinocyte chemoattractant (KC), MCP-1, MIP-2, IL-1β, IL-10, IL-13, IL-33, IL-4, IL-5, and IL-6 | ProcartaPlex |
Formaldehyde exposure induces differentiation of regulatory T cells via the NFAT‑mediated T cell receptor signalling pathway in Yucatan minipigs | Investigation of formaldehyde exposure and resulting toxicological effects on minipigs. | IL-4, IFN-γ, TNF-α | ProcartaPlex |
Topical application of the quaternary ammonium compound didecyldimethylammonium chloride activates type 2 innate lymphoid cells and initiates a mixed-type allergic response | Study of the hypersensitivity immune responses in murine models upon dermal exposure of an industrial/commercial compound. | Th1/Th2/Th9/Th17/Th22/Treg Cytokine 17-Plex Mouse ProcartaPlex Panel | ProcartaPlex |
Effects of different surface modifying agents on the cytotoxic and antimicrobial properties of ZnO nanoparticles | Evaluation of cytotoxic properties of surface-modified ZnO nanoparticles by investigating inflammatory cytokine production in human cells. | Inflammation 20-Plex Human ProcartaPlex Panel | ProcartaPlex |
Evaluation of IL-1 blockade as an adjunct to linezolid therapy for tuberculosis in mice and macaques | Assessment of reduced hematopoietic toxicity in a non-human primate model by addition of alpha-IL-IR1 to linezolid regimen. | Cytokine & Chemokine 30-Plex NHP ProcartaPlex Panel | ProcartaPlex |
Combined toxicity of air pollutants related to e-waste on inflammatory cytokines linked with neurotransmitters and pediatric behavioral problems | Study of the toxicological effects of e-waste inhalation in humans. | IL-1β, IL-6, TNF-α | ProcartaPlex |
ELISA kits can be used to detect and measure a variety of biomarkers that may be activated in toxicological settings. These kits can be used with a variety of biological sources and enable researchers to study the possible effects of toxins on different pathways in vivo, in distinct species.
ProQuantum immunoassays are highly sensitive, high-performance kits used to detect target proteins with limited volume and do not require any specialized instruments. These assays utilize proximity-based amplification technology and combine analyte-specific high-affinity antibody-antigen binding with signal detection and amplification. These capabilities are similar to qPCR and help achieve a simple yet powerful next-generation protein quantitation platform.
ProcartaPlex panels allow concurrent detection and measurement of soluble biomarkers implicated in toxin administration. Select one of our pre-configured panels described below or use the panel configurator to customize a panel best suited to your research needs associated with toxicology research and testing.
ProcartaPlex assays for kidney toxicity enable the simultaneous quantification of up to 11 toxicity targets (including FDA-recommended biomarkers) in a single well [4]. These assays are available in multiple formats including pre-configured off-the-shelf panels, simplex kits, and custom blended mix and match panels that are tested against different sample types such as urine, serum/plasma, and cell culture supernatant.
Figure 3. Urinary protein markers in acute kidney injury (AKI) and renal kidney failure (RKF) patient samples. The Kidney Toxicity 11-plex Human ProcartaPlex Panel 1 and Kidney Toxicity 9-plex Human ProcartaPlex Panel 2 were used to test key urinary protein markers in individuals. Data shows significantly increased markers in urine samples of 10 AKI and 13 RKF individuals compared to controls (healthy donor).
Cat. No. | Name | Size |
---|---|---|
EPX110-15855-901 | Kidney Toxicity 11-plex Human ProcartaPlex Panel 1 KIM-1/HAVCR/TIM-1 (Kidney injury molecule 1), Renin, Calbindin, Osteoactivin/GPNMB (Transmembrane Glycoprotein NMB), GSTA1 (Glutathione S-transferase A1), IL-18, IP-10 (CXCL10), MCP-1 (CCL2), VEGF-A, Clusterin (APO-J), RBP4 (Retinol-binding protein 4) | 96 tests |
EPX090-15856-901 | Kidney Toxicity 9-plex Human ProcartaPlex Panel 2 Uromodulin, Alpha-1-microglobulin, TFF3 (Trefoil factor 3), Osteopontin (OPN), Cystatin C, NGAL, Beta-2-microglobulin (B2M), TIMP-1, EGF | 96 tests |
EPX050-30124-901 | Kidney Toxicity 5-Plex Rat ProcartaPlex Panel 1 Calbindin, KIM-1, Osteopontin (OPN), TFF3, VEGF-A | 96 tests |
EPX050-30125-901 | Kidney Toxicity 5-Plex Rat ProcartaPlex Panel 2 Albumin, Cystatin, Clusterin (Apo-J), NGAL, TIMP-1 | 96 tests |
QuantiGene RNA gene expression assays provide a fast and high-throughput solution for multiplexed gene expression quantitation, with simultaneous measurement of up to 80 genes of interest in a single well of a 96- or 384-well plate. The QuantiGene Plex assay is based on hybridization, and incorporates branched DNA (bDNA) technology, which uses signal amplification rather than target amplification for direct measurement of RNA transcripts. The assay is run on the Luminex® platform, has a simple workflow, and does not require RNA purification. These features allow the user to merge the QuantiGene workflow for gene expression profiling with the ProcartaPlex workflow for protein quantitation (Figure 5) using the same sample.
Learn more about QuantiGene RNA assays for gene expression profiling
Figure 5. Combined workflow for QuantiGene gene expression and ProcartaPlex protein quantitation assays.
For Research Use Only. Not for use in diagnostic procedures.